NF‑κB is negatively associated with Nurr1 to reduce the inflammatory response in Parkinson's disease

Gao,Hua; Wang,Dan; Jiang,Sen; Mao,Jieping; Yang,Xinling

doi:10.3892/mmr.2021.12035

NF‑κB is negatively associated with Nurr1 to reduce the inflammatory response in Parkinson's disease

Authors:
- Hua Gao
- Dan Wang
- Sen Jiang
- Jieping Mao
- Xinling Yang
View Affiliations

Affiliations: Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830063, P.R. China, Department of Neurology, Urumqi Friendship Hospital, Urumqi, Xinjiang 830049, P.R. China
Published online on: March 25, 2021 https://doi.org/10.3892/mmr.2021.12035
Article Number: 396

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Parkinson's disease (PD) is one of the most disabling diseases of the central nervous system, seriously affecting health and quality of life for the elderly. The present study aimed to explore the effects of nuclear receptor subfamily 4 group A member 2 (Nurr1) and nuclear factor‑κB (NF‑κB) on the progression of Parkinson's disease (PD). Pheochromocytoma (PC12) cells were pretreated with the NF‑κB inhibitor quinazoline (QNZ) or transfected with small interfering (si)RNA‑NF‑κB, followed by the addition of lipopolysaccharide (LPS). After culturing for 24 h, Cell Counting Kit‑8 (CCK‑8) was utilized to measure cell viability. Next, the expression levels of interleukin (IL)‑1β, IL‑6 and tumor necrosis factor (TNF)‑α were determined using the relevant Enzyme‑linked immunosorbent assay kits. Expression levels of p65, tyrosine hydroxylase (TH), α‑Synuclein (A‑SYN) and Nurr1 were examined by immunofluorescence and western blotting. CCK‑8 results showed that the cell viability was significantly reduced in the LPS group than in the control group (P<0.05), whereas QNZ and si‑NF‑κB demonstrated significantly enhanced viability induced by LPS (P<0.05). After LPS induction, the levels of IL‑1β, IL‑6 and TNF‑α were significantly elevated when compared with those in the control group (P<0.05), whereas QNZ and NF‑κB interference partially restored their levels. Additionally, after LPS induction, the expression of p65 and A‑SYN was higher, while the expression of TH and Nurr1 was lower. However, QNZ and NF‑κB treatment significantly reversed the expression levels induced by LPS (P<0.05). Finally, it was observed that NF‑κB may be negatively associated with Nurr1. In conclusion, inhibition of NF‑κB may reduce the production of inflammatory factors by upregulating Nurr1 and TH and downregulating A‑SYN, thus relieving the inflammatory response in PD.

View Figures

View References

1	Sveinbjornsdottir S: The clinical symptoms of Parkinson's disease. J Neurochem. 139 (Suppl 1):S318–S324. 2016. View Article : Google Scholar
2	Cacabelos R: Parkinson's disease: From pathogenesis to pharmacogenomics. Int J Mol Sci. 18:5512017. View Article : Google Scholar
3	Radhakrishnan DM and Goyal V: Parkinson's disease: A review. Neurol India. 66 (Suppl):S26–S35. 2018. View Article : Google Scholar : PubMed/NCBI
4	Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE and Pahan K: Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA. 104:18754–18759. 2007. View Article : Google Scholar : PubMed/NCBI
5	Katzenschlager R and Lees AJ: Treatment of Parkinson's disease: Levodopa as the first choice. J Neurol. 249 (Suppl 2):II19–II24. 2002. View Article : Google Scholar : PubMed/NCBI
6	Csoti I, Jost WH and Reichmann H: Parkinson's disease between internal medicine and neurology. J Neural Transm (Vienna). 123:3–17. 2016. View Article : Google Scholar : PubMed/NCBI
7	Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, et al: Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis. Lancet Neurol. 16:55–65. 2017. View Article : Google Scholar : PubMed/NCBI
8	Wen KX, Miliç J, El-Khodor B, Dhana K, Nano J, Pulido T, Kraja B, Zaciragic A, Bramer WM, Troup J, et al: The role of DNA methylation and histone modifications in neurodegenerative diseases: A systematic review. PLoS One. 11:e01672012016. View Article : Google Scholar : PubMed/NCBI
9	Roostalu U, Salinas CBG, Thorbek DD, Skytte JL, Fabricius K, Barkholt P, John LM, Jurtz VI, Knudsen LB, Jelsing J, et al: Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease. Dis Model Mech. 12:dmm0422002019. View Article : Google Scholar : PubMed/NCBI
10	Wang X, Yang HA, Wang XN and Du YF: Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease. Genet Mol Res. 15:2016.
11	Salemme A, Togna AR, Mastrofrancesco A, Cammisotto V, Ottaviani M, Bianco A and Venditti A: Anti-inflammatory effects and antioxidant activity of dihydroasparagusic acid in lipopolysaccharide-activated microglial cells. Brain Res Bull. 120:151–158. 2016. View Article : Google Scholar : PubMed/NCBI
12	Bessler H, Djaldetti R, Salman H, Bergman M and Djaldetti M: IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother. 53:141–145. 1999. View Article : Google Scholar : PubMed/NCBI
13	Jing H, Wang S, Wang M, Fu W, Zhang C and Xu D: Isobavachalcone attenuates MPTP-induced Parkinson's disease in mice by inhibition of microglial activation through NF-κB pathway. PLoS One. 12:e01695602017. View Article : Google Scholar : PubMed/NCBI
14	Wang J, Yang ZH, Chen H, Li HH, Chen LY, Zhu Z, Zou Y, Ding CC, Yang J and He ZW: Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer. BMC Cancer. 16:2572016. View Article : Google Scholar : PubMed/NCBI
15	Bonta PI, Pols TW, van Tiel CM, Vos M, Arkenbout EK, Rohlena J, Koch KT, de Maat MP, Tanck MW, de Winter RJ, et al: Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation. Circulation. 121:2023–2032. 2010. View Article : Google Scholar : PubMed/NCBI
16	McEvoy AN, Murphy EA, Ponnio T, Conneely OM, Bresnihan B, FitzGerald O and Murphy EP: Activation of nuclear orphan receptor NURR1 transcription by NF-kappa B and cyclic adenosine 5′-monophosphate response element-binding protein in rheumatoid arthritis synovial tissue. J Immunol. 168:2979–2987. 2002. View Article : Google Scholar : PubMed/NCBI
17	Pasban-Aliabadi H, Esmaeili-Mahani S, Sheibani V, Abbasnejad M, Mehdizadeh A and Yaghoobi MM: Inhibition of 6-hydroxydopamine-induced PC12 cell apoptosis by olive (Olea europaea L.) leaf extract is performed by its main component oleuropein. Rejuvenation Res. 16:134–142. 2013. View Article : Google Scholar : PubMed/NCBI
18	Wu C, Zhao W, Yu J, Li S, Lin L and Chen X: Induction of ferroptosis and mitochondrial dysfunction by oxidative stress in PC12 cells. Sci Rep. 8:5742018. View Article : Google Scholar : PubMed/NCBI
19	Sahoo S, Meijles DN, Al Ghouleh I, Tandon M, Cifuentes-Pagano E, Sembrat J, Rojas M, Goncharova E and Pagano PJ: MEF2C-MYOCD and leiomodin1 suppression by miRNA-214 promotes smooth muscle cell phenotype switching in pulmonary arterial hypertension. PLoS One. 11:e01537802016. View Article : Google Scholar : PubMed/NCBI
20	Xu G, Ao R, Zhi Z, Jia J and Yu B: miR-21 and miR-19b delivered by hMSC-derived EVs regulate the apoptosis and differentiation of neurons in patients with spinal cord injury. J Cell Physiol. 234:10205–10217. 2019. View Article : Google Scholar : PubMed/NCBI
21	Cheng S, Jiang X, Ding C, Du C, Owusu-Ansah KG, Weng X, Hu W, Peng C, Lv Z, Tong R, et al: Expression and critical role of interleukin enhancer binding factor 2 in hepatocellular carcinoma. Int J Mol Sci. 17:13732016. View Article : Google Scholar
22	Rizzo F, Riboldi G, Salani S, Nizzardo M, Simone C, Corti S and Hedlund E: Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell Mol Life Sci. 71:999–1015. 2014. View Article : Google Scholar : PubMed/NCBI
23	Russo I, Bubacco L and Greggio E: LRRK2 and neuroinflammation: Partners in crime in Parkinson's disease? J Neuroinflamm. 11:522014. View Article : Google Scholar
24	Aloor R, Zhang C, Bandyopadhyay M and Dasgupta S: Impact of nuclear factor-κB on restoration of neuron growth and differentiation in hippocampus of degenerative brain. J Neurosci Res. 93:1471–1475. 2015. View Article : Google Scholar : PubMed/NCBI
25	Negi G, Kumar A and Sharma SS: Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: Effects on NF-κB and Nrf2 cascades. J Pineal Res. 50:124–131. 2011.PubMed/NCBI
26	Wei X and Shao X: Nobiletin alleviates endometriosis via down-regulating NF-κB activity in endometriosis mouse model. Biosci Rep. 38:BSR201804702018. View Article : Google Scholar : PubMed/NCBI
27	Song F, Sun H, Wang Y, Yang H, Huang L, Fu D, Gan J and Huang C: Pannexin3 inhibits TNF-α-induced inflammatory response by suppressing NF-κB signalling pathway in human dental pulp cells. J Cell Mol Med. 21:444–455. 2017. View Article : Google Scholar : PubMed/NCBI
28	Santos CM: New agents promote neuroprotection in Parkinson's disease models. CNS Neurol Disord Drug Targets. 11:410–418. 2012. View Article : Google Scholar : PubMed/NCBI
29	Burre J, Sharma M and Sudhof TC: Cell biology and pathophysiology of α-synuclein. Cold Spring Harb Perspect Med. 8:a0240912018. View Article : Google Scholar : PubMed/NCBI
30	Ma J, Yuan L, Wang SJ, Lei J, Wang Y, Li YN and Yu BL: Electroacupuncture improved locomotor function by regulating expression of tyrosine hydroxylase and α-synuclein proteins and transcription activating factor 6 and transcription factor X box binding protein 1 mRNAs in substantia nigra of rats with Parkinson's disease. Zhen Ci Yan Jiu. 44:805–809. 2019.(In Chinese). PubMed/NCBI
31	Mani S, Sekar S, Barathidasan R, Manivasagam T, Thenmozhi AJ, Sevanan M, Chidambaram SB, Essa MM, Guillemin GJ and Sakharkar MK: Naringenin decreases α-synuclein expression and neuroinflammation in MPTP-Induced Parkinson's disease model in mice. Neurotox Res. 33:656–670. 2018. View Article : Google Scholar : PubMed/NCBI
32	Shao QH, Yan WF, Zhang Z, Ma KL, Peng SY, Cao YL, Yuan YH and Chen NH: Nurr1: A vital participant in the TLR4-NF-κB signal pathway stimulated by α-synuclein in BV-2cells. Neuropharmacology. 144:388–399. 2019. View Article : Google Scholar : PubMed/NCBI
33	Wang X, Zhuang W, Fu W and Wang X, Lv E, Li F, Zhou S, Rausch WD and Wang X: The lentiviral-mediated Nurr1 genetic engineering mesenchymal stem cells protect dopaminergic neurons in a rat model of Parkinson's disease. Am J Transl Res. 10:1583–1599. 2018.PubMed/NCBI
34	Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, Gage FH and Glass CK: A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 137:47–59. 2009. View Article : Google Scholar : PubMed/NCBI